Ichnos Sciences strikes exclusive global deal with Astria Therapeutics for OX40 antibody portfolio

Ichnos Sciences, a prominent clinical-stage biotechnology firm specializing in pioneering multispecific antibodies for oncology and under the ownership of Glenmark Pharmaceuticals, has announced a momentous ... Read More